734 860
[18]
Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn’t it increase at the rate of inflation? Arch Intern Med 2003;163:1637.
[19]
Marseille E, Larson B, Kazi DS, et al. Thresholds for the cost- effectiveness of interventions: alternative approaches. Bull World Health Organ 2015;93:118–24.[20]
Shiroiwa T, Sung Y-K, Fukuda T, Lang H-C, Bae S-C, Tsutani K. International survey on willingness-to-pay (WTP) for one addition- al QALY gained: what is the threshold of cost effectiveness? Health Econ 2010;19:422–37.[21]
Mouraviev V, Nosnik I, Sun L, et al. Financial comparative analysis of minimally invasive surgery to open surgery for localized prostate cancer: a single-institution experience. Urology 2007;69:311–4.
[22]
Riley GF. Administrative and claims records as sources of health care cost data. Med Care 2009;47:S51–5.
[23]
Leow JJ, Chang SL, Meyer CP, et al. Robot-assisted versus open radical prostatectomy: a contemporary analysis of an all-payer discharge database. Eur Urol 2016;70:837–45.
[24]
Basto M, Sathianathen N, TeMarvelde L, et al. Patterns-of-care and health economic analysis of robot-assisted radical prostatectomy in the Australian public health system. BJU Int 2016;117:930–9.
[25]
Scales Jr CD, Jones PJ, Eisenstein EL, Preminger GM, Albala DM. Local cost structures and the economics of robot assisted radical prosta- tectomy. J Urol 2005;174:2323–9.[26]
Abdollah F, Buda¨us L, Sun M, et al. Impact of caseload on total hospital charges: a direct comparison between minimally invasive and open radical prostatectomy—a population based study. J Urol 2011;185:855–61.[27]
Niklas C, Saar M, Berg B, et al. da Vinci and open radical prostatec- tomy: comparison of clinical outcomes and analysis of insurance costs. Urol Int 2016;96:287–94.
[28]
Hughes D, Camp C, O’Hara J, Adshead J. Health resource use after robot-assisted surgery vs open and conventional laparoscopic tech- niquesinoncology: analysisof English secondary care data forradical prostatectomy and partial nephrectomy. BJU Int 2016;117:940–7.[29]
Bijlani A, Hebert AE, DavitianM, et al. Amultidimensional analysis of prostate surgery costs in the united states: robotic-assisted versus retropubic radical prostatectomy. Value Health 2016;19:391–403.[30]
Miller DC, Gust C, Dimick JB, Birkmeyer N, Skinner J, Birkmeyer JD. Large variations in Medicare payments for surgery highlight sav- ings potential from bundled payment programs. Health Aff Proj Hope 2011;30:2107–15.
[31]
Shih Y-CT, Ward JF, Pettaway CA, et al. Comparative effectiveness, cost, and utilization of radical prostatectomy among young men withinmanaged care insurance plans. Value Health 2012;15:367–75.[32]
Epstein AJ, Groeneveld PW, Harhay MO, Yang F, Polsky D. Impact of minimally invasive surgery on medical spending and employee absenteeism. JAMA Surg 2013;148:641–7.
[33]
Kim SP, Gross CP, Smaldone MC, et al. Perioperative outcomes and hospital reimbursement by type of radical prostatectomy: results from a privately insured patient population. Prostate Cancer Pros- tatic Dis 2015;18:13–7.
[34]
Bai G, Anderson GF. Extreme markup: the fifty US hospitals with the highest charge-to-cost ratios. Health Aff (Millwood) 2015;34:922–8.[35]
Cooperberg MR, Ramakrishna NR, Duff SB, et al. Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysis. BJU Int 2013;111:437–50.
[36]
Eldefrawy A, Katkoori D, Abramowitz M, Soloway MS, Manoharan M. Active surveillance vs. treatment for low-risk prostate cancer: a cost comparison. Urol Oncol 2013;31:576–80.
[37]
O’Malley SP, Jordan E. Review of a decision by the Medical Services Advisory Committee based on health technology assessment of an emerging technology: The case for remotely assisted radical pros- tatectomy. Int J Technol Assess Health Care 2007;23:286–91.[38]
Hohwu¨ L, Borre M, Ehlers L, Venborg Pedersen K. A short-term cost- effectiveness study comparing robot-assisted laparoscopic and open retropubic radical prostatectomy. J Med Econ 2011;14: 403–9.[39]
Nguyen PL, Gu X, Lipsitz SR, et al. Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol 2011;29:1517–24.
[40]
Yong JHE, Beca J, McGowan T, Bremner KE, Warde P, Hoch JS. Cost- effectiveness of intensity-modulated radiotherapy in prostate can- cer. Clin Oncol 2012;24:521–31.
[41]
Konski A. Cost-effectiveness of intensity-modulated radiation ther- apy. Expert Rev Pharmacoecon Outcomes Res 2005;5:137–40.[42]
Yong JHE, McGowan T, Redmond-Misner R, et al. Estimating the costs of intensity-modulated and 3-dimensional conformal radio- therapy in Ontario. Curr Oncol 2016;23:e228–38.[43] Zemple´nyi A t., Kalo´ Z, Kova´cs G, et al. Cost-effectiveness analysis of
intensity-modulated radiation therapy with normal and hypofrac-
tionated schemes for the treatment of localised prostate cancer. Eur
J Cancer Care (Engl). In press.
http://dx.doi.org/10.1111/ecc.12430.
[44]
Carter HE, Martin A, Schofield D, et al. A decision model to estimate the cost-effectiveness of intensity modulated radiation therapy (IMRT) compared to three dimensional conformal radiation thera- py (3DCRT) in patients receiving radiotherapy to the prostate bed. Radiother Oncol 2014;112:187–93.[45]
Konski A, Speier W, Hanlon A, Beck JR, Pollack A. Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate? J Clin Oncol 2007;25:3603–8.
[46]
Lundkvist J, Ekman M, Ericsson SR, Jo¨nsson B, Glimelius B. Proton therapy of cancer: potential clinical advantages and cost-effective- ness. Acta Oncol 2005;44:850–61.
[47]
Yaxley JW, Coughlin GD, Chambers SK, et al. Robot-assisted lapa- roscopic prostatectomy versus open radical retropubic prostatec- tomy: early outcomes from a randomised controlled phase 3 study. Lancet 2016;388:1057–66.
[48]
Novara G, Ficarra V, Mocellin S, et al. Systematic review and meta- analysis of studies reporting oncologic outcome after robot- assisted radical prostatectomy. Eur Urol 2012;62:382–404.
[49]
Ficarra V, Novara G, Rosen RC, et al. Systematic review and meta- analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur Urol 2012;62:405–17.
[50]
Ficarra V, Novara G, Ahlering TE, et al. Systematic review and meta- analysis of studies reporting potency rates after robot-assisted radical prostatectomy. Eur Urol 2012;62:418–30.
[51]
Yu T, Zhang Q, Zheng T, et al. The effectiveness of intensity modu- lated radiation therapy versus three-dimensional radiation therapy in prostate cancer: a meta-analysis of the literatures. PLoS One 2016;11:e0154499.
[52]
Hall EJ. Wuu C-S. Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int J Radiat Oncol 2003;56:83–8.
[53] Proton therapy vs. IMRT for low or intermediate risk prostate
cancer PARTIQoL 2016.
https://clinicaltrials.gov/ct2/show/ NCT01617161.
[54]
Moon DH, Efstathiou JA, Chen RC. What is the best way to radiate the prostate in 2016? Urol Oncol 2017;35:59–68.
[55]
Fang P, Mick R, Deville C, et al. A case-matched study of toxicity outcomes after proton therapy and intensity-modulated radiation therapy for prostate cancer. Cancer 2015;121:1118–27.
[56]
Gray PJ, Paly JJ, Yeap BY, et al. Patient-reported outcomes after 3- dimensional conformal, intensity-modulated, or proton beam ra- diotherapy for localized prostate cancer. Cancer 2013;119:1729–35.
[57]
Hoppe BS, Michalski JM, Mendenhall NP, et al. Comparative effec- tiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer. Cancer 2014;120:1076–82.E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 7 1 2 – 7 3 5
734